Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 177 posts found.

Tyvber image

GSK and Roche get EU breast cancer indication

August 15, 2013
Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer

The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …

News
fda image

FDA gives Perjeta priority

July 3, 2013
Sales and Marketing FDA, Perjeta, Roche, breast cancer

The FDA has granted priority review status to an application for Roche’s Perjeta to be used before surgery in HER2-positive …

News
Afinitor image

Afinitor’s new UK indication launched

September 20, 2012
Sales and Marketing Afinitor, CHMP, Novartis, breast cancer

Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …

News
Avastin image

Another NICE no for Avastin in breast cancer

August 22, 2012
Sales and Marketing NICE, avastin, breast cancer, rejection

Roche’s Avastin has been rejected once again for use in breast cancer patients.  NICE has now issued final guidance saying …

News
Roche image

Roche winning on Perjeta supply, but running short of Boniva

August 20, 2012
Manufacturing and Production, Sales and Marketing Boniva, Perjeta, Roche, breast cancer

Roche is getting production for its new breast cancer drug Perjeta back on track after some initial teething troubles, but …

News
Avastin pack shot

NICE no for Avastin in breast cancer

July 6, 2012
Sales and Marketing NICE, Roche, avastin, breast cancer, rejection

NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …

News
Roche image

Roche’s Perjeta increases survival

June 27, 2012
Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer

Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …

News

FDA approves Roche’s breast cancer drug

June 11, 2012
Sales and Marketing EMA, FDA, Perjeta, Roche, breast cancer

US regulators have approved Roche’s new breast cancer drug after granting it a priority review to speed up the process. …

News
avastin

NICE rejects Avastin for breast cancer

April 18, 2012
Sales and Marketing EMA, NICE, Roche, avastin, breast cancer

In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …

News
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News
Breast cancer image

Breast cancer treatment – the next advances

February 7, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, CDF, Lorena Tonarelli, T-DM1, breast cancer, pertuzumab

When a close member of my family was diagnosed with breast cancer, the doctors didn’t give us much hope. They …

Feature
Tyverb picture

GSK’s Tyverb fails late-stage trial in breast cancer

December 12, 2011
Research and Development, Sales and Marketing GSK, Tyverb, breast cancer

GlaxoSmithKline’s Tyverb has failed to help women with HER2 positive breast cancer increase their survival.  The TEACH study’s primary objective …

News
Roche picture

Roche’s new breast cancer drug succeeds in late-stage trial

December 9, 2011
Research and Development, Sales and Marketing Roche, breast cancer, pertuzumab

Roche’s next generation breast cancer drug pertuzumab has helped patients to live over six months longer. CLEOPATRA, the first randomised …

News

NICE will not back Eisai’s Halaven

November 17, 2011
Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

News
Avastin pack shot

FDA’s rejection of Avastin creates conflict

October 31, 2011
Research and Development, Sales and Marketing FDA, avastin, breast cancer

Oncology experts have expressed concern at the FDA’s rejection of Roche’s Avastin for the treatment of advanced breast cancer. A …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025